ReviewWorld journal of hepatology2013
Life cycle and pathogenesis of hepatitis D virus: A review.
Review in World journal of hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 70 citations in OpenAlex.
- Natural Alkaloids Against Liver Injury: Mechanistic Insights and Multi-Target Therapeutic Potential.Biomolecules · 2026Review
- Review
- Diversity and evolution of viroids and viroid-like agents with circular RNA genomes revealed by metatranscriptome mining.Nucleic acids research · 2025Article
- Chronic Hepatitis D Virus Infection and Its Treatment: A Narrative Review.Microorganisms · 2024Review
- Acacetin, a Natural Flavone with Potential in Improving Liver Disease Based on Its Anti-Inflammation, Anti-Cancer, Anti-Infection and Other Effects.Molecules (Basel, Switzerland) · 2024Review
- Molecular Epidemiology of Hepatitis D Virus in the North-East Region of Romania.Pathogens (Basel, Switzerland) · 2024Article
- Hepatitis B Virus Infection: A Mini Review.Viruses · 2024Review
- Impacts of Surface Characteristics and Dew Point on the Blue-Light (BLMicroorganisms · 2023Article
- Virus Behavior after UVMicroorganisms · 2023Article
- Hepatitis Delta Infection: A Clinical Review.Seminars in liver disease · 2023Review
- Diagnosis of HDV: From virology to non-invasive markers of fibrosis.Liver international : official journal of the International Association for the Study of the Liver · 2023Review
- Recent treatment advances and practical management of hepatitis D virus.Clinical medicine (London, England) · 2023Review
- Pre- and Post-Transcriptional Control of HBV Gene Expression: The Road Traveled towards the New Paradigm of HBx, Its Isoforms, and Their Diverse Functions.Biomedicines · 2023Review
- Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D.Frontiers in medicine · 2023Article
- Article
- Hepatitis Delta: Current Knowledge and Future Directions.Gastroenterology & hepatology · 2022Article
- Viral hepatitis: Past, present, and future.World journal of gastroenterology · 2022Review
- Immune disorders and rheumatologic manifestations of viral hepatitis.World journal of gastroenterology · 2021Review
- Hepatitis D virus and liver transplantation: Indications and outcomes.World journal of hepatology · 2021Review
- Hepatitis D infection: from initial discovery to current investigational therapies.Gastroenterology report · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis D virus (HDV) is a defective RNA virus which requires the help of hepatitis B virus (HBV) virus for its replication and assembly of new virions. HDV genome contains only one actively transcribed open reading frame which encodes for two isoforms of hepatitis delta antigen. Post-translational modifications of small and large delta antigens (S-HDAg and L-HDAg) involving phosphorylation and isoprenylation respectively confer these antigens their specific properties. S-HDAg is required for the initiation of the viral genome replication, whereas L-HDAg serves as a principal inhibitor of replication and is essential for the assembly of new virion particles. Immune mediation has usually been implicated in HDV-associated liver damage. The pathogenesis of HDV mainly involves interferon-α signaling inhibition, HDV-specific T-lymphocyte activation and cytokine responses, and tumor necrosis factor-alpha and nuclear factor kappa B signaling. Due to limited protein coding capacity, HDV makes use of host cellular proteins to accomplish their life cycle processes, including transcription, replication, post-transcriptional and translational modifications. This intimate host-pathogen interaction significantly alters cell proteome and is associated with an augmented expression of pro-inflammatory, growth and anti-apoptotic factors which explains severe necroinflammation and increased cell survival and an early progression to hepatocellular carcinoma in HDV patients. The understanding of the process of viral replication, HBV-HDV interactions, and etio-pathogenesis of the severe course of HDV infection is helpful in identifying the potential therapeutic targets in the virus life cycle for the prophylaxis and treatment of HDV infection and complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.